Fetal RHD Screening in RH1 Negative Pregnant Women: Experience in Switzerland

Bernd Schimanski, Rahel Kräuchi, Jolanda Stettler, Sofia Lejon Crottet, Christoph Niederhauser, Frederik Banch Clausen, Stefano Fontana, Markus Hodel, Sofia Amylidi-Mohr, Luigi Raio, Claire Abbal, Christine Henny*

*Corresponding author af dette arbejde


RH1 incompatibility between mother and fetus can cause hemolytic disease of the fetus and newborn. In Switzerland, fetal RHD genotyping from maternal blood has been recommended from gestational age 18 onwards since the year 2020. This facilitates tailored administration of RH immunoglobulin (RHIG) only to RH1 negative women carrying a RH1 positive fetus. Data from 30 months of noninvasive fetal RHD screening is presented. Cell-free DNA was extracted from 7192 plasma samples using a commercial kit, followed by an in-house qPCR to detect RHD exons 5 and 7, in addition to an amplification control. Valid results were obtained from 7072 samples, with 4515 (64%) fetuses typed RHD positive and 2556 (36%) fetuses being RHD negative. A total of 120 samples led to inconclusive results due to the presence of maternal or fetal RHD variants (46%), followed by women being serologically RH1 positive (37%), and technical issues (17%). One sample was typed false positive, possibly due to contamination. No false negative results were observed. We show that unnecessary administration of RHIG can be avoided for more than one third of RH1 negative pregnant women in Switzerland. This reduces the risks of exposure to a blood-derived product and conserves this limited resource to women in actual need.

Udgave nummer10
StatusUdgivet - 27 sep. 2023


Dyk ned i forskningsemnerne om 'Fetal RHD Screening in RH1 Negative Pregnant Women: Experience in Switzerland'. Sammen danner de et unikt fingeraftryk.